Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has entered into an exclusive agreement with Cilag AG International, a Johnson & Johnson affiliate, to develop, manufacture and market ceftobiprole, Basilea's novel broad-spectrum antibiotic.
Subscribe to our email newsletter
Ceftobiprole has activity against methicillin-resistant Staphylococcus aureus (MRSA) and is in phase III clinical trials in complicated skin and skin structure infections, with hospital-acquired pneumonia trials also in preparation. Both indications have been granted fast track designation by the FDA.
Under the terms of the agreement, Basilea will receive a substantial upfront payment and is eligible for additional payments on achievement of pre-specified clinical, regulatory and sales milestones. Upfront and milestone payments may together total up to CHF370 million and Basilea will also receive significant double-digit royalties on worldwide sales.
Ortho-McNeil Pharmaceutical, another Johnson & Johnson company, will market ceftobiprole in the US and its affiliate companies, known as Janssen-Cilag, will market the product outside the US. Basilea has retained an option to co-promote ceftobiprole in the US, in major European countries, Japan and China.
Ortho-McNeil’s research affiliate, Johnson & Johnson Pharmaceutical R&D, will develop ceftobiprole in collaboration with Basilea.